or
forgot password

A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN


Phase 1
18 Years
N/A
Not Enrolling
Both
Lymphoma

Thank you

Trial Information

A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN


Inclusion Criteria:



- Patients with AML, a certain type of ALL, NHL and MM

- certain types of cancer of the lymph nodes

- certain types of leukemias (blood cancers)

- disease has or will fail with other treatments

- relatively good overall health other than your cancer

Exclusion Criteria:

- poor bone marrow function (not producing enough blood cells)

- serious heart conditions

- poor liver or kidney function

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Judith Ochs, MD

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca

Authority:

United States: Food and Drug Administration

Study ID:

D2782C00002

NCT ID:

NCT00460460

Start Date:

March 2007

Completion Date:

August 2007

Related Keywords:

  • Lymphoma
  • Phase I
  • cancer
  • lymphoma
  • leukemia
  • myeloma
  • AML
  • ALL
  • NHL
  • MM
  • Lymphoma
  • Hematologic Neoplasms

Name

Location
Research Site Albany, New York